Close
  Indian J Med Microbiol
 

Figure 4: Proportion of women protected by intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). Simulated patients were given either three doses of IPTp-SP as currently recommended by the World Health Organization (WHO)[4] or 4, 6, 8 weekly-doses of IPTp or two doses as previously recommended by the WHO[10] with each row representing a different adherence scenario (Scenario 2, 3, 4, 5, 6, 7) full adherence is shown in rows Scenario 1, 8, 9 10, 11 and 12 respectively. For illustrative purposes, the proportion of women protected at each time point was arbitrarily categorised as >95% (green), >75 to 95% (yellow), >50 to 75% (orange) and ≤50% (red).

Figure 4: Proportion of women protected by intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). Simulated patients were given either three doses of IPTp-SP as currently recommended by the World Health Organization (WHO)<sup>[4]</sup> or 4, 6, 8 weekly-doses of IPTp or two doses as previously recommended by the WHO<sup>[10]</sup> with each row representing a different adherence scenario (Scenario 2, 3, 4, 5, 6, 7) full adherence is shown in rows Scenario 1, 8, 9 10, 11 and 12 respectively. For illustrative purposes, the proportion of women protected at each time point was arbitrarily categorised as >95% (green), >75 to 95% (yellow), >50 to 75% (orange) and ≤50% (red).